共 71 条
[1]
Siegel RL(2019)Cancer statistics, 2019 CA Cancer J Clin 69 7-34
[2]
Miller KD(1941)Studies on prostatic cancer - I the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 293-297
[3]
Jemal A(2005)Osteoblasts in prostate cancer metastasis to bone Nat Rev Cancer 5 21-28
[4]
Huggins C(2010)Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 1437-1446
[5]
Hodges CV(2013)Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis J Biol Chem 288 19359-19369
[6]
Logothetis CJ(2013)Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling Cell Death Dis 4 e764-E550
[7]
Lin SH(2013)Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer PLoS One 8 1-6224
[8]
Scher HI(2015)Castration-induced acceleration of bone metastasis prevented by rank inhibitor Osteoprotegerin in murine castration-resistant prostate cancer model J Urol 193 E549-252
[9]
Lin TH(2017)Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer Sci Signal 10 492-62254
[10]
Lin TH(2017)Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis Oncogene 36 6213-160